October 13 , 2015 AtriCure Completes Acquisition of nContact WEST CHESTER, Ohio – October 13 , 2015 – AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibr

AtriCure Completes Acquisition of nContact

WEST CHESTER, Ohio October 13, 2015 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has completed its previously announced acquisition of nContact, Inc., a privately held developer of innovative cardiac ablation solutions.

nContact's mission is to transform the underserved arrhythmia market through the advancement of less invasive ablation alternatives for cardiac arrhythmias. The Company is conducting the CONVERGE IDE Clinical Trial, the first head-to-head study to evaluate the Convergent Procedure to catheter ablation in persistent atrial fibrillation patients. The Company's lead technology, Epi-Sense Coagulation System with VisiTrax , has CE Mark approval in Europe for the coagulation of cardiac tissue in the treatment of atrial fibrillation and atrial flutter. The Epi-Sense Coagulation System with VisiTrax is indicated for endoscopic coagulation of cardiac tissue in the U.S. nContact was founded in 2005 and is headquartered in Morrisville, North Carolina, USA. For more information, visit www.ncontactinc.com.

Senior Vice President and Chief Financial Officer

Investor Relations Contact